Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies.
作者信息
Garattini Silvio, Natsis Yannis, Banzi Rita
机构信息
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
European Public Health Alliance, Brussels, Belgium.
出版信息
Front Pharmacol. 2021 Apr 28;12:685604. doi: 10.3389/fphar.2021.685604. eCollection 2021.
Abstract
摘要
相似文献
1
Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies.欧洲制药战略：对公共卫生驱动的药物研发、监管及政策的思考
Front Pharmacol. 2021 Apr 28;12:685604. doi: 10.3389/fphar.2021.685604. eCollection 2021.
2
European healthcare policies for controlling drug expenditure.欧洲控制药品支出的医疗政策。
Pharmacoeconomics. 2003;21(2):89-103. doi: 10.2165/00019053-200321020-00002.
3
Generic Medicine Pricing Policies in Europe: Current Status and Impact.欧洲仿制药定价政策：现状与影响
Pharmaceuticals (Basel). 2010 Mar 5;3(3):471-481. doi: 10.3390/ph3030471.
4
Network on veterinary medicines initiated by the European Federation For Pharmaceutical Sciences.由欧洲药物科学联合会发起的兽药网络。
J Vet Pharmacol Ther. 2018 Jun;41(3):378-383. doi: 10.1111/jvp.12472. Epub 2017 Dec 20.
5
Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.迈向欧洲药品研究战略（2014-2020 年）：欧盟制药工业协会联合会关于“地平线 2020”计划的立场文件。
Eur J Pharm Sci. 2012 Dec 18;47(5):979-87. doi: 10.1016/j.ejps.2012.09.020. Epub 2012 Oct 6.
6
Public-private partnership models in France and in Europe.法国及欧洲的公私合作模式。
Therapie. 2006 Jul-Aug;61(4):325-34, 313-23. doi: 10.2515/therapie:2006059.
7
Pharmaceutical policies: effects of financial incentives for prescribers.药品政策：针对开处方者的经济激励措施的影响。
Cochrane Database Syst Rev. 2007 Jul 18(3):CD006731. doi: 10.1002/14651858.CD006731.
8
Value added medicines: what value repurposed medicines might bring to society?增值药物：重新利用的药物可能给社会带来什么价值？
J Mark Access Health Policy. 2016 Dec 23;5(1):1264717. doi: 10.1080/20016689.2017.1264717. eCollection 2017.
9
Future European health care: cost containment, health care reform and scientific progress in drug research.未来的欧洲医疗保健：成本控制、医疗改革与药物研究的科学进展。
Int J Health Plann Manage. 1997 Apr-Jun;12(2):81-101. doi: 10.1002/(SICI)1099-1751(199704)12:2<81::AID-HPM460>3.0.CO;2-3.
10
National and local antibiotic policies in Central and Eastern Europe.中东欧国家和地方的抗生素政策。
J Chemother. 2000 Dec;12(6):471-4. doi: 10.1179/joc.2000.12.6.471.
引用本文的文献
1
Advancing Regulatory Oversight of Medical Device Trials to Align with Clinical Drug Standards in the European Union.推进欧盟医疗器械试验的监管监督，使其与临床药物标准保持一致。
Pharmaceuticals (Basel). 2025 Jun 12;18(6):876. doi: 10.3390/ph18060876.
2
Citizens' views on prices of medicines reimbursed by the National Health Service: Findings from Italian online focus groups.公民对国家医疗服务体系报销药品价格的看法：来自意大利在线焦点小组的调查结果
Health Expect. 2024 Apr;27(2):e14005. doi: 10.1111/hex.14005.
3
Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries.20个国家的先进治疗药品定价与报销机制
Front Pharmacol. 2023 Nov 28;14:1199500. doi: 10.3389/fphar.2023.1199500. eCollection 2023.
4
Developing a national pharmaceutical research strategy in Lebanon: opportunities to bridge the gaps and reach the goals.制定黎巴嫩国家制药研究战略：弥合差距并实现目标的机遇。
J Pharm Policy Pract. 2022 Nov 17;15(1):83. doi: 10.1186/s40545-022-00485-1.
本文引用的文献
1
Quality, efficacy, safety-it is not enough!质量、疗效、安全——这还不够！
Eur J Clin Pharmacol. 2021 Sep;77(9):1425-1426. doi: 10.1007/s00228-021-03110-3. Epub 2021 Mar 9.
2
The COVID-19 pandemic: a catalyst to improve clinical trials.新冠疫情：改善临床试验的催化剂。
Nat Rev Cardiol. 2020 Nov;17(11):673-675. doi: 10.1038/s41569-020-00439-7.
3
From blockbuster to "nichebuster": how a flawed legislation helped create a new profit model for the drug industry.从重磅炸弹药物到“小众炸弹药物”：一项有缺陷的立法如何助力制药行业创造新的盈利模式。
BMJ. 2020 Jul 28;370:m2983. doi: 10.1136/bmj.m2983.
4
New drugs: where did we go wrong and what can we do better?新药：我们错在哪里，如何才能做得更好？
BMJ. 2019 Jul 10;366:l4340. doi: 10.1136/bmj.l4340.
5
Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.罕见病药物，孤儿病。欧盟孤儿药立法的第一个十年。
Eur J Clin Pharmacol. 2013 Apr;69(4):1009-24. doi: 10.1007/s00228-012-1423-2. Epub 2012 Oct 23.
6
Patients and the public deserve big changes in evaluation of drugs.患者和公众理应在药物评估方面看到重大变革。
BMJ. 2009 Mar 31;338:b1025. doi: 10.1136/bmj.b1025.
Zotero 插件